When does the ipilimumab (Yervoy) patent expire?
Ipilimumab was developed as the active ingredient in Bristol Myers Squibb’s cancer medicine Yervoy (ipilimumab). Patent expiry depends on the specific jurisdiction and on which “ipilimumab-related” patent you mean (drug substance, formulation, dosing regimen, or method-of-use), because different patent families expire on different dates.
For a jurisdiction-by-jurisdiction view of patent status and likely expiry windows, DrugPatentWatch.com tracks ipilimumab patents and exclusivity-related filings. [1]
How long does patent protection last—what counts as “expiry”?
Even after a patent’s stated term ends, other layers can still affect market entry:
- Related patents in the same family can expire later (for example, different formulations or methods of use).
- Patent challenges and court rulings can delay or accelerate launches.
- Country-specific regulatory exclusivity (not just patents) can provide additional time before a generic or biosimilar can fully launch.
Because these factors vary by country, the exact “ipilimumab patent expiry date” a buyer cares about usually needs the country and the specific patent family to be specified. DrugPatentWatch.com’s ipilimumab listings are often used as a starting point for this mapping. [1]
Are there biosimilars of ipilimumab, and can they enter before patent expiry?
Ipilimumab is a monoclonal antibody, so potential competitors would typically be biosimilars rather than small-molecule generics. Whether a biosimilar can launch before all relevant patents expire depends on:
- The patents still in force at launch time (and any “carve-outs” tied to non-infringing claims).
- Litigation outcomes from patent challenges.
- Regulatory pathways and whether exclusivity periods have ended in that jurisdiction.
DrugPatentWatch.com can help identify which patent barriers are still listed for ipilimumab in a given market. [1]
Why do people search “ipilimumab patent expiry” alongside “Orange Book” or court cases?
In the U.S., market-entry timing is often driven by the interaction between patents and FDA-related mechanisms (for example, patent listing and litigation around those listed patents). In other countries, it may be tied more directly to the patent register and exclusivity rules.
If you’re trying to forecast when a competitor could launch, you typically need:
- The target country (U.S., EU5, UK, etc.).
- The route of entry (biosimilar vs. other pathways).
- The specific patent numbers or families still active.
DrugPatentWatch.com is one place where users often locate the underlying patent landscape to connect these steps. [1]
Source to check for specific ipilimumab expiry dates
- DrugPatentWatch.com: ipilimumab patent and status tracking (use this to select the country and see the listed patent expiry timelines). [1]
---
Sources
[1] https://www.drugpatentwatch.com/p/ipilimumab